Company intelligence / Profile preview

Lipella Pharmaceuticals

Pittsburgh, Pennsylvania, United Stateslipella.com ↗

Ownership: Public · LIPO
Employees: ~7
Development stage: Phase 2

Overview

Lipella has completed a Phase 2a trial of LP‑10 in hemorrhagic cystitis and is planning a Phase 2b trial. INDs are approved for LP‑310 and LP‑410, with Phase 2a studies in oral lichen planus and oral GvHD expected to begin in late 2024/early 2025. The company’s proprietary liposomal platform is protected by patents through at least 2035.

Therapeutic areas: OncologyImmunologyNephrology
Modalities: Small moleculeLiposomal drug delivery therapyImmunoglobulin therapy (for LP-50)
Industry: Biotech

Drug pipeline

4 assets

LP-08

3 more assets in the full pipeline.

Partnerships

No major pharma partnerships disclosed as of June 2025; open to strategic partnerships/licensing

Financials

Market cap: $2.3K
Total revenue: $536.4K
Enterprise value: $-1.6M

Beyond the preview

Go deeper on Lipella Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lipella Pharmaceuticals.